Outbreak of respiratory infection: nCoV-2019 current status and its impact on global health

2020 ◽  
Vol 16 ◽  
Author(s):  
Saurabh Kumar ◽  
Sandeep Kumar ◽  
Adil Karim ◽  
Kamlesh Bisht ◽  
Abdul Ghani ◽  
...  
Keyword(s):  
T Cells ◽  
Clinical Symptoms ◽  
Cytotoxic T Cells ◽  
Respiratory Illness ◽  
Current Status ◽  
Global Pandemic ◽  
High Infection ◽  
Epidemiology Data ◽  
Rapid Transmission ◽  
Novel Coronavirus

: Novel Coronavirus-2019 (nCoV-2019) emerged as a potentially infectious respiratory disease caused by newly discovered β-coronavirus. nCoV-19 has emerged as a global pandemic due to the rapid transmission and high infection rate commonly involved in acute respiratory illness. Literature search includes various databases like Google Scholar, PubMed, ScienceDirect, and Scopus for studies published using a different combination of keywords “coronavius”, “COVID-19”, “SARS”, “MERS”, “antiviral drugs”, “vaccines”, and “immunity”. We collected epidemiology data from the Worldometer portal (data available till 9 October, 2020). Fever, dry cough, dyspnea, sore throat, or fatigue are common clinical symptoms of the infection. Cytotoxic T-cells and T-helper cells Cytotoxic T cells (CD8+) accounts for maximum (approximately 80%) of total infiltrate in the pulmonary region of the affected nCoV individuals and acts as a significant contributor in the clearance of the infection. This review intends to outline the literature concerning the mode of actual transmission, immune response, and possible therapeutic approach against the virus.

scholarly journals COVID-19, T Cells, Cytokines and Immunotherapy: Review

2021 ◽  
pp. 70-82
Author(s):  
Nesrin I. Tarbiah
Keyword(s):  
Immune Response ◽  
T Cells ◽  
Viral Infections ◽  
Cytotoxic T Cells ◽  
Clinical Findings ◽  
Global Pandemic ◽  
Significant Step ◽  
Novel Coronavirus ◽  
Cellular Immune ◽  
Cell Expression

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus (COVID-19), materialized in the city of Wuhan and quickly spread to form a global pandemic. An essential role in the immune system is undertaken by lymphocytes, which defend against bacteria, viruses, fungi, and parasites. Previous study found that very severe COVID-19 patients had suppression of the immune response enabling the virus to spread and cause more damage. This was evident by the changes in their white blood cell and lymphocyte count. Early clinical findings suggest that those suffering from severe COVID-19 have reduced numbers of lymphocytes, monocytes, and other granulocytes. One of the most efficient responses for a variety of viral infections is cellular immune response activation, especially via T cells. Viruses can be eliminated by T cytotoxic (CD8+) (Tc) in the host body, these secrete a variety of molecules, including interferons (IFNs), granzyme, and perforin. T helper (CD4+) (Th) cells help by assisting cytotoxic T cells and B cells to eliminate viral infection. CD8+ and CD4+ work together in a coordinated immune response with other constituents to primarily resolve acute viral infections, and after to produce protection against any reinfection. Also, COVID-19 causes dramatic changes in cytokine profiles and serological markers. Therefore, the subsets of immune cells and the level of the pro-inflammatory cytokines are crucial evidence to determine the severity of COVID-19. The disease severity has already been proved to be associated with the disruption in the proinflammatory chemokine response, this eventually leads to a cytokine storm and progression of cytokines release syndrome (CRS). This review aimed to demonstrate a full understanding of the alterations to the immune response by determining the T-cell expression and cytokine levels against the pathological processes of COVID-19, which can be a significant step in early treatment and diagnosis of this disease, in reduction of COVID-19 mortality cases, and to emphasize the most recent and current studies to try to identify new immuno-therapeutics for COVID-19.  

Novel Coronavirus Disease (COVID-19): A Narrative Review Based on Current Status

2020 ◽  
Vol 18 ◽  
Author(s):  
Rina Das ◽  
Dinesh Kumar Mehta ◽  
Meenakshi Dhanawat
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Clinical Symptoms ◽  
Virus Disease ◽  
Relevant Literature ◽  
World Health ◽  
Current Status ◽  
Future Research ◽  
Treatment And Prevention ◽  
First Case ◽  
Novel Coronavirus

Abstract:: A novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appeared and expanded globally by the end of year in 2019 from Wuhan, China, causing severe acute respiratory syndrome. During its initial stage, the disease was called the novel coronavirus (2019-nCoV). It was named COVID-19 by the World Health Organization (WHO) on 11 February 2020. The WHO declared worldwide the SARS-CoV-2 virus a pandemic on March 2020. On 30 January 2020 the first case of Corona Virus Disease 2019 (COVID-19) was reported in India. Now in current situation the virus is floating in almost every part of the province and rest of the globe. -: On the basis of novel published evidences, we efficiently summarized the reported work with reference to COVID-19 epidemiology, pathogen, clinical symptoms, treatment and prevention. Using several worldwide electronic scientific databases such as Pubmed, Medline, Embase, Science direct, Scopus, etc were utilized for extensive investigation of relevant literature. -: This review is written in the hope of encouraging the people successfully with the key learning points from the underway efforts to perceive and manage SARS-CoV-2, suggesting sailent points for expanding future research.

scholarly journals Covid-19 and food security: Jeopardy management and posterity deliberations

2021 ◽  
Vol 10 (2) ◽  
pp. 01-05
Author(s):  
Augustine Owusu-Addo ◽  
Atianashie Miracle A ◽  
Chukwuma Chinaza Adaobi ◽  
Larissa Agbemelo-Tsomafo
Keyword(s):  
Food Processing ◽  
Respiratory Illness ◽  
The United States ◽  
The Novel ◽  
Food Handling ◽  
Global Pandemic ◽  
Food Borne ◽  
Novel Coronavirus ◽  
Food Borne Infections ◽  
Safety Guidelines

COVID-19, also known as the ‘novel coronavirus disease 2019’, is a respiratory illness and the causative pathogen is officially named as ‘SARS-CoV-2’. Infections with SARS-CoV-2 have now been amplified to a global pandemic – as of April 3, 2020, nearly 1,018,000 cases have been confirmed in more than 195 countries, including more than 300,000 cases within the United States. Public safety guidelines are followed worldwide to stop the spread of COVID-19 and stay healthy. Despite COVID-19 is a respiratory illness with mode of invasion through the respiratory tract, not the gastrointestinal tract, an average food consumer is anxious and concerned about the food safety. Could an individual catch the deadly contagious COVID-19 from groceries brought home from the supermarket – or from the next restaurant takeout order? This brief review elucidates the epidemiology and pathobiological mechanism(s) of SARS-CoV-2 and its implications in food-borne infections, transmission via food surfaces, food processing and food handling.

Current Trends and Future Strategies for the Global Impact of COVID-19 Pandemic

Coronaviruses ◽  
2021 ◽  
Vol 02 ◽  
Author(s):  
Ashutosh Chauhan ◽  
Ankit Kumar ◽  
Sandeep Goyal ◽  
Sunil Kumar Joshi ◽  
Deepak Kumar Semwal
Keyword(s):  
Relevant Information ◽  
Current Status ◽  
Stage Of Development ◽  
Current Trends ◽  
Global Pandemic ◽  
Future Challenges ◽  
Preclinical Trials ◽  
The Usa ◽  
Novel Coronavirus ◽  
Treatment Procedures

ABSTRACT: Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) might have originated from the recombination of a Pangolin-CoV-like virus with a Bat-CoV-RaTG13-like virus and then transmitted to the human at Wuhan city of China. On February 11, 2020, the WHO announced a name for the new coronavirus disease as COVID-19. Finally, the WHO declared the novel coronavirus outbreak a global pandemic on March 11, 2020. Within a few months, SARS-CoV-2 had spread across the world in 220 Countries, areas or territories. The main objective of this work is to review the existing knowledge about COVID-19, its updated status, available treatment procedures and future challenges. The available literature based on the COVID-19 was thoroughly reviewed and concise evidence-based information was explored for the public interest. Various authentic databases like PubMed, Scopus, and Google Scholar together with the official sites of some Govt. Organizations were carefully searched for all relevant information about the current status of COVID-19 including the published research on coronavirus. More than 68 million people are already infected including around 20% severely ill with almost 1.5 million casualties due to this virus and expected to infect approximate 70% population worldwide. Currently, maximum confirmed cases and death are reported in the USA. The epicentre of the pandemic was initially shifted from China to Europe then to the USA, Brazil and now India. In between, understanding of pathogenesis and mode of transmission has been developed; repurposing drugs are being validated and development of a new vaccine is underway. The study concludes that there is no established treatment available for COVID-19, although 26 clinical and 139 preclinical trials are underway to develop vaccines globally. Although three vaccines are in advance stage of development, their efficacy and adverse effect yet to be validated and recorded. Recently, Pfizer vaccine has been started vaccination for emergency uses in England and Bahrain, and the United State of America will start it soon. Meanwhile, prevention, rigorous global containment and quarantine efforts are practiced worldwide to control its spread.

scholarly journals SARS-CoV-2, ACE2 expression, and systemic organ invasion

2020 ◽  
Author(s):  
Usman M Ashraf ◽  
Ahmed A Abokor ◽  
Jonnelle M. Edwards ◽  
Emily W. Waigi ◽  
Rachel S. Royfman ◽  
...  
Keyword(s):  
Respiratory Illness ◽  
Normal Function ◽  
Multiple Organ ◽  
Angiotensin Converting Enzyme 2 ◽  
Multiple Organs ◽  
Global Pandemic ◽  
Organ Systems ◽  
Novel Coronavirus ◽  
Severe Respiratory Illness ◽  
Organ Invasion

A novel coronavirus disease, COVID-19, has created a global pandemic in 2020, posing an enormous challenge to healthcare systems and affected communities. COVID-19 is caused by Severe Acute Respiratory Syndrome (SARS)-CoronaVirus-2 (CoV-2) that manifests as bronchitis, pneumonia, or a severe respiratory illness. SARS-CoV-2 infects human cells via binding a "spike" protein on its surface to angiotensin-converting enzyme 2 (ACE2) within the host. ACE2 is crucial for maintaining tissue homeostasis and negatively regulates the renin-angiotensin-aldosterone system (RAAS) in the humans. The RAAS is paramount for normal function in multiple organ systems including the lungs, heart, kidney, and vasculature. Given that SARS-CoV-2 internalizes via ACE2, the resultant disruption in ACE2 expression can lead to altered tissue function and exacerbate chronic diseases. The widespread distribution and expression of ACE2 across multiple organs is critical to our understanding of the varied clinical outcomes of COVID-19. This perspective review based on the current literature was prompted to show how disruption of ACE2 by SARS-CoV-2 can affect different organ systems.

scholarly journals The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting

2020 ◽  
Vol 17 (16) ◽  
pp. 5648 ◽  
Author(s):  
Hossein Hozhabri ◽  
Francesca Piceci Sparascio ◽  
Hamidreza Sohrabi ◽  
Leila Mousavifar ◽  
René Roy ◽  
...  
Keyword(s):  
Clinical Manifestations ◽  
Weather Conditions ◽  
Respiratory Illness ◽  
Health Concern ◽  
Current Status ◽  
Global Public Health ◽  
Infected People ◽  
Published Evidence ◽  
Human Coronaviruses ◽  
Novel Coronavirus

Over the past two decades, there have been two major outbreaks where the crossover of animal Betacoronaviruses to humans has resulted in severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). In December 2019, a global public health concern started with the emergence of a new strain of coronavirus (SARS-CoV-2 or 2019 novel coronavirus, 2019-nCoV) which has rapidly spread all over the world from its origin in Wuhan, China. SARS-CoV-2 belongs to the Betacoronavirus genus, which includes human SARS-CoV, MERS and two other human coronaviruses (HCoVs), HCoV-OC43 and HCoV-HKU1. The fatality rate of SARS-CoV-2 is lower than the two previous coronavirus epidemics, but it is faster spreading and the large number of infected people with severe viral pneumonia and respiratory illness, showed SARS-CoV-2 to be highly contagious. Based on the current published evidence, herein we summarize the origin, genetics, epidemiology, clinical manifestations, preventions, diagnosis and up to date treatments of SARS-CoV-2 infections in comparison with those caused by SARS-CoV and MERS-CoV. Moreover, the possible impact of weather conditions on the transmission of SARS-CoV-2 is also discussed. Therefore, the aim of the present review is to reconsider the two previous pandemics and provide a reference for future studies as well as therapeutic approaches.

scholarly journals The Role of Glucocorticoids in the Management of COVID-19

2020 ◽  
Vol 53 (01) ◽  
pp. 9-15
Author(s):  
Vasileia Ismini Alexaki ◽  
Holger Henneicke
Keyword(s):  
Inflammatory Diseases ◽  
Respiratory Illness ◽  
The Novel ◽  
Diverse Range ◽  
Global Pandemic ◽  
Frontline Treatment ◽  
Systemic Glucocorticoids ◽  
Emerging Issues ◽  
Life Threatening ◽  
Novel Coronavirus

AbstractCoronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19.

scholarly journals E-cigarette or vaping product use-associated lung injury (EVALI) masquerading as COVID-19

2021 ◽  
Vol 14 (7) ◽  
pp. e243885
Author(s):  
Nandita Ganne ◽  
Raj Palraj ◽  
Elizabeth Husted ◽  
Ishan Shah
Keyword(s):  
Acute Lung Injury ◽  
Lung Injury ◽  
Respiratory Distress ◽  
Clinical Symptoms ◽  
Antibody Test ◽  
The Novel ◽  
Product Use ◽  
Global Pandemic ◽  
Novel Coronavirus ◽  
Intravenous Steroids

SARS-CoV-2, the novel coronavirus causing COVID-19, has caused a global pandemic resulting in over 4 million deaths globally (data current as of 14 July 2021). E-cigarette or vaping product use-associated lung injury (EVALI) is a type of acute lung injury of unclear pathogenesis. The two pathologies present with overlapping clinical symptoms, laboratory values and imaging, making them difficult to distinguish, especially in the setting of a global COVID-19 pandemic. We present the case of a 32-year-old woman treated for COVID-19 despite multiple negative SARS CoV-2 PCR tests and nucleocapsid antibody test. On further investigation, she endorsed use of E-cigarettes and was subsequently diagnosed with EVALI. The patient was treated with oral and intravenous steroids, resulting in significant improvement in her symptoms. This case highlights the challenge of diagnosing rarer aetiologies of respiratory distress during the COVID-19 pandemic.

scholarly journals COVID-19 Global Pandemic Planning: Decontamination and Reuse Processes for N95 Respirators

2020 ◽  
Author(s):  
Douglas J Perkins ◽  
Steven Villescas ◽  
Terry H. Wu ◽  
Timothy Muller ◽  
Steven Bradfute ◽  
...  
Keyword(s):  
Operating Room ◽  
Healthcare Providers ◽  
Respiratory Illness ◽  
Lessons Learned ◽  
Healthcare Personnel ◽  
Environmental Controls ◽  
Global Pandemic ◽  
Increased Risk ◽  
Novel Coronavirus ◽  
N95 Respirators

ABSTRACTCoronavirus disease 2019 (COVID-19) is an illness caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified as a cluster of respiratory illness in Wuhan City, Hubei Province, China in December 2019, and has rapidly spread across the globe to greater than 200 countries. Healthcare providers are at an increased risk for contracting the disease due to occupational exposure and require appropriate personal protective equipment (PPE), including N95 respirators. The rapid worldwide spread of high numbers of COVID-19 cases has facilitated the need for a substantial supply of PPE that is largely unavailable in many settings, thereby creating critical shortages. Creative solutions for the decontamination and safe reuse of PPE to protect our frontline healthcare personnel are essential. Here, we describe the development of a process that began in late February 2020 for selecting and implementing the use of hydrogen peroxide vapor (HPV) as viable method to reprocess N95 respirators. Since pre-existing HPV decontamination chambers were not available, we optimized the sterilization process in an operating room after experiencing initial challenges in other environments. Details are provided about the prioritization and implementation of processes for collection and storage, pre-processing, HPV decontamination, and post-processing of filtering facepiece respirators (FFRs). Important lessons learned from this experience include, developing an adequate reserve of PPE for effective reprocessing and distribution, and identifying a suitable location with optimal environmental controls (i.e., operating room). Collectively, information presented here provides a framework for other institutions considering decontamination procedures for N95 respirators.

New Viral Infection COVID-19: Current Status, Challenges and Possible Treatments

2020 ◽  
Vol 18 ◽  
Author(s):  
Vipan Kumar ◽  
Amruta Suryan ◽  
Jyoti Singh ◽  
Sandeep Kumar ◽  
Pradeep Kamboj ◽  
...  
Keyword(s):  
Treatment Options ◽  
Antiviral Agents ◽  
Viral Envelope ◽  
Current Status ◽  
Effective Vaccine ◽  
Plasma Therapy ◽  
Immunomodulatory Agents ◽  
Global Pandemic ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Since December 2019, the prevalence of novel coronavirus infection (named as COVID-19 by WHO on Feb 11, 2020) has become a growing healthcare concern worldwide. On March 11, 2020, the WHO declared COVID-19 a global pandemic. As no specific approved treatment options are available for the COVID-19 infection, several existing antiviral drugs in combination with others have become mainstay therapy. The targets for the treatment of the infection include viral targets such as polymerases, spike glycoproteins, membrane proteins, and viral envelope and host targets such as host proteases and host receptors. Antiviral agents, immunomodulatory agents, and empiric broad-spectrum antibiotics can be used as treatment therapies for the infection. Convalescent plasma therapy has also been proposed as an effective treatment for COVID-19. Additionally, many studies are ongoing to develop a potent and effective vaccine that completely blocks SARS-CoV-2. Nevertheless, prevention of spreading of the virus remains the first and foremost step towards controlling and managing the coronavirus infection.

Sign in / Sign up

Export Citation Format

Share Document